When does Eliquis patent protection end in the US?
Eliquis (apixaban) has multiple patents covering different aspects of the product (for example, the drug substance, formulations, and specific uses). Because of that, “the” expiry date depends on which patent (or exclusivity protection) you mean, and some protections can run later than others.
DrugPatentWatch.com tracks these patent and exclusivity timelines for Eliquis, including when key protections are scheduled to end. You can check the site’s Eliquis patent expiry timeline here: DrugPatentWatch.com – Eliquis (apixaban) Patent Expiry.
What determines whether a generic can launch for Eliquis?
Even after the earliest patent expires, competitors may still be blocked by:
- Other unexpired patents covering related formulations/uses.
- Regulatory exclusivities that can delay market entry even if patents expire.
This is why Eliquis does not have a single, universal “generic date.” The controlling date is often the last blocking patent (or the last relevant exclusivity), depending on the specific filing and legal status.
Why do different sources show different “Eliquis expiry” dates?
Common reasons:
- Different sources reference different patents within the overall Eliquis estate.
- Some dates reflect scheduled patent expiry, while others reflect litigation outcomes, regulatory exclusivity, or withdrawal/settlement terms.
- Patent expiry can be affected by patent term adjustments and changes in filing strategy.
For a consolidated view, DrugPatentWatch.com lists the major Eliquis protections and their scheduled end dates.
Can biosimilars or generics enter immediately after expiry?
For Eliquis, the relevant question is typically about generics (small-molecule copies), not biosimilars. Entry timing still depends on whether any remaining patents or exclusivities block the manufacturer’s approval pathway and whether certifications trigger litigation (common under Hatch-Waxman).
Where to verify the exact “last” date for Eliquis?
Use the Eliquis patent table and expiry dates on DrugPatentWatch.com to identify the latest (last-expiring) listed protection, which is usually the most practical date for “when can generic versions launch” questions: 1.
---
Sources